Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Sinocelltech Group Ltd
688520Sinocelltech Group Limited, a biotech company, engages in the research and development, and industrialization of recombinant proteins, monoclonal antibodies, and vaccines in China. The company offers AnpingxiA (repertuzumab injection), an anti-tumor product; Anjiayin for the treatment of the rare disease hemophilia A; coronavirus 2-valent, a trimer protein vaccine; and mutant strain recombinant protein vaccines SCTV01C and SCTV01E. Its pipeline products include SCT630 used for the treatment of autoimmune diseases; SCT510 for the treatment of solid tumors; SCT-I10A, a monoclonal antibody injection which is in phase 3 trials for the treatment of solid tumors; SCTV01, a new generation vaccine which is in phase 3 trials for the treatment of corona virus; SCT510 for the treatment of solid tumors; SCT200, a monoclonal antibody injection for the treatment of solid tumors; and SCT1000, which is in phase 3 clinical trials for the treatment of human papillomavirus, as well as SCTA01 which is in phase 2/3 clinical research trials for the treatment of SARS COV-2. The company was founded in 2007 and is based in Beijing, China. Sinocelltech Group Limited operates as a subsidiary of Lhasa Alike Investment Consulting Co., Ltd. Address: No. 31 Kechuang 7th Street, Beijing, China, 100176
Analytics
Precio Objetivo de WallStreet
470.11 CNYRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave 688520
Análisis de dividendos 688520
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout 688520
Valoración de la acción 688520
Finanzas 688520
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |